GT Biopharma, Inc.(GTBP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
GTBP Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for GT Biopharma, Inc. (GTBP), a Healthcare sector company. GTBP is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of GTBP by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, VANGUARD FIDUCIARY, based on the most recent SEC filings. GTBP trades on the Nasdaq exchange and files with the SEC under CIK 109657. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GTBP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GT Biopharma, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-4.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-115.4% YoYOperating Income
+13.5% YoYEPS (Diluted)
+3.7% YoYTotal Assets
+91.5% YoYOp. Cash Flow
-0.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0.00 |
| Net Income | $-28.4M -115.4% | $-13.2M -73.3% | $-7.6M +63.6% | $-20.9M +64.0% | $-58.0M -105.0% | $-28.3M |
| Operating Income | $-12.4M +13.5% | $-14.4M -5.8% | $-13.6M +36.1% | $-21.3M +63.0% | $-57.5M -750.3% | $-6.8M |
| EPS (Diluted) | $-6.68 +3.7% | $-6.94 -23.0% | $-5.64 +71.3% | $-19.66 | — | — |
| Total Assets | $8.1M +91.5% | $4.2M -70.0% | $14.1M -15.7% | $16.7M -48.0% | $32.2M +468.3% | $5.7M |
| Operating Cash Flow | $-12.9M -0.1% | $-12.9M -45.8% | $-8.9M +41.8% | $-15.2M +2.5% | $-15.6M -114.9% | $-7.3M |
Get alerted when GTBP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for GT Biopharma, Inc. including:
Top Institutional Holders of GTBP
VANGUARD CAPITAL MANAGEMENT LLC
$184.4K376,399 shGEODE CAPITAL MANAGEMENT, LLC
$130.6K266,788 shVANGUARD FIDUCIARY TRUST CO
$110.7K225,938 shHRT FINANCIAL LP
$52.0K107,140 shEverhart Financial Group, Inc.
$49.0K100,000 shSRS Capital Advisors, Inc.
$45.9K93,627 shOpal Wealth Advisors, LLC
$40.1K81,811 shNORTHERN TRUST CORP
$37.0K75,461 sh49 WEALTH MANAGEMENT, LLC
$31.3K64,000 shALONGSIDE, LLC
$31.3K64,000 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $184.4K | 376,399 |
| GEODE CAPITAL MANAGEMENT, LLC | $130.6K | 266,788 |
| VANGUARD FIDUCIARY TRUST CO | $110.7K | 225,938 |
| HRT FINANCIAL LP | $52.0K | 107,140 |
| Everhart Financial Group, Inc. | $49.0K | 100,000 |
| SRS Capital Advisors, Inc. | $45.9K | 93,627 |
| Opal Wealth Advisors, LLC | $40.1K | 81,811 |
| NORTHERN TRUST CORP | $37.0K | 75,461 |
| 49 WEALTH MANAGEMENT, LLC | $31.3K | 64,000 |
| ALONGSIDE, LLC | $31.3K | 64,000 |
More Healthcare Companies
View all Healthcare →Put GTBP on your watchlist
Track score changes the day GT Biopharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GTBP a good stock to buy?
13F Pro's AI-powered analysis of GT Biopharma, Inc. (GTBP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GTBP are available on the GTBP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GTBP is classified as a small company.
Which hedge funds own GTBP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GTBP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GT Biopharma, Inc.'s investment landscape.